GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » EPS (Diluted)

Anavex Life Sciences (STU:12X1) EPS (Diluted) : €-0.51 (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences EPS (Diluted)?

Anavex Life Sciences's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was €-0.13. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.51.

Anavex Life Sciences's EPS (Basic) for the three months ended in Dec. 2024 was €-0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.51.

Anavex Life Sciences's EPS without NRI for the three months ended in Dec. 2024 was €-0.13. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.51.

During the past 3 years, the average EPS without NRIGrowth Rate was 0.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -2.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was -3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Anavex Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 35.30% per year. The lowest was -257.60% per year. And the median was -4.10% per year.


Anavex Life Sciences EPS (Diluted) Historical Data

The historical data trend for Anavex Life Sciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences EPS (Diluted) Chart

Anavex Life Sciences Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.38 -0.46 -0.63 -0.56 -0.47

Anavex Life Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.12 -0.13 -0.13 -0.13

Competitive Comparison of Anavex Life Sciences's EPS (Diluted)

For the Biotechnology subindustry, Anavex Life Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's PE Ratio falls into.



Anavex Life Sciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Anavex Life Sciences's Diluted EPS for the fiscal year that ended in Sep. 2024 is calculated as

Diluted EPS (A: Sep. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-38.745-0)/83.468
=-0.46

Anavex Life Sciences's Diluted EPS for the quarter that ended in Dec. 2024 is calculated as

Diluted EPS (Q: Dec. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-11.566-0)/84.806
=-0.14

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anavex Life Sciences  (STU:12X1) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Anavex Life Sciences EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Anavex Life Sciences Headlines

No Headlines